Furthermore, PTEN loss has been consistently associated with adverse clinical outcomes, including poor overall survival, unfavourable pathological tumour behaviour, and the development of castration-resistant and metastatic PCa (69, 83). This evidence concerns the gene PTEN and neoplasm.